Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1802560
Original Article

Optimizing Oncological Care in Patients with End-Stage Chronic Kidney Disease on Dialysis: Indian Scenario

Nihanthy D. Sreenath 
1   Department of Medical Oncology, Sindhu Hospital, Hyderabad, Telangana, India
,
Naveen Kumar Kushwaha 
2   Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Kaushik M. R. 
3   Department of Medical Oncology, INHS Asvini, Mumbai, Maharashtra, India
,
Rajath Govind 
4   Department of Medical Oncology, Army Hospital (Research & Referral), New Delhi, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background In India, around 55,000 patients are on dialysis, with a 10–20% annual increase. With the growing dialysis population in India, cancer risk among end-stage renal disease (ESRD) patients is increasing. Managing chemotherapy in these patients is challenging due to limited data and guidelines, leading to treatment uncertainty.

Objectives This study provides real-world data from India on the clinical management and outcomes of cancer patients with ESRD undergoing dialysis while receiving chemotherapy.

Material and Methods This prospective study analyzed data from five cancer patients with end-stage renal disease (ESRD) on hemodialysis prior to diagnosis of cancer treated at a tertiary oncology center in India. We analyzed the demographic details, cancer staging, treatment regimens, and dosage adjustments. Treatment modifications due to renal dysfunction, toxicities, and patient outcomes were also reviewed over a 12-month follow-up.

Results The cohort consisted of 80% (4/5 pts) females, with a median age of 57.8 years. Hypertensive and diabetic nephropathy were the leading causes of ESRD. Cancers included breast (3/5 pts), lung (1/5 pts), and ovarian (1/5 pts), with varying stages of diagnosis. 80% (4/5) of patients required tailored drug management. The Ovarian cancer patient experienced severe hypersensitivity to carboplatin, which was managed conservatively. No grade 3/4 immune-related adverse events occurred, and all patients were alive and disease-free at the one-year follow-up.

Conclusion Carefully tailored treatment strategies and a coordinated multidisciplinary approach allowed positive outcomes for cancer patients on dialysis, emphasizing the need for personalized approaches. These findings highlight the importance of refining treatment protocols for this complex group.

Keywords

end-stage renal disease - hemodialysis - cancer - immunotherapy - targeted therapy

Declaration of Generative AI and AI-Assisted Technologies in the Writing Process

During the preparation of this work, the authors used Chat-GPT to improve language and readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.


Authors' Contributions

N.D.S. performed the initial manuscript write-up, data collection, literature review, and manuscript editing. N.K.K. assisted with the final write-up, data collection, literature review, and editing of the manuscript. K.M.R. and R.G. assisted in data collection and literature review.


Patient Consent

Written informed consent was obtained from the patients.




Publication History

Article published online:
20 February 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Chien CC, Han MM, Chiu YH. et al. Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer 2017; 8 (01) 9-18
    CrossrefPubMedSearch in Google Scholar
  • 2 Janus N, Launay-Vacher V, Deray G, Thyss A, Thariat J. Management of chemotherapy in hemodialysis patients. Bull Cancer 2012; 99 (03) 371-380
    PubMedSearch in Google Scholar
  • 3 Janus N, Launay-Vacher V, Thyss A. et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 2013; 24 (02) 501-507
    CrossrefPubMedSearch in Google Scholar
  • 4 Czarnecka AM, Kawecki M, Lian F, Korniluk J, Szczylik C. Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future Oncol 2015; 11 (16) 2267-2282
    CrossrefPubMedSearch in Google Scholar
  • 5 Janus N, Launay-Vacher V. Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis. Expert Opin Drug Metab Toxicol 2017; 13 (06) 617-623
    CrossrefPubMedSearch in Google Scholar
  • 6 Arantes Jr LH, Crawford J, Gascon P. et al. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol 2018; 129: 79-90
    CrossrefPubMedSearch in Google Scholar
  • 7 Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23 (03) 253-262
    PubMedSearch in Google Scholar
  • 8 Sprangers B, Jhaveri KD, Perazella MA. Improving cancer care for patients with chronic kidney disease. J Clin Oncol 2020; 38 (03) 188-192
    CrossrefPubMedSearch in Google Scholar
  • 9 Kitchlu A, Shapiro J, Amir E. et al. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA 2018; 319 (23) 2437-2439
    CrossrefPubMedSearch in Google Scholar
  • 10 Levey AS, de Jong PE, Coresh J. et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80 (01) 17-28
    CrossrefPubMedSearch in Google Scholar
  • 11 Kitchlu A, Jhaveri KD, Sprangers B, Yanagita M, Wanchoo R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J 2021; 14 (09) 2012-2022
    CrossrefPubMedSearch in Google Scholar
  • 12 Bermejo S, Bolufer M, Riveiro-Barciela M, Soler MJ. Immunotherapy and the spectrum of kidney disease: should we individualize the treatment?. Front Med (Lausanne) 2022; 9: 906565
    CrossrefPubMedSearch in Google Scholar
  • 13 Silvestris N, Argentiero A, Cosmai L. et al. Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2019; 140: 39-51
    CrossrefPubMedSearch in Google Scholar
  • 14 Modi G, Jha V. Incidence of ESRD in India. Kidney Int 2011; 79 (05) 573
    CrossrefPubMedSearch in Google Scholar
  • 15 Pedrazzoli P, Silvestris N, Santoro A. et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). ESMO Open 2017; 2 (03) e000167
    CrossrefPubMedSearch in Google Scholar
  • 16 Schupp N, Heidland A, Stopper H. Genomic damage in endstage renal disease-contribution of uremic toxins. Toxins (Basel) 2010; 2 (10) 2340-2358
    CrossrefPubMedSearch in Google Scholar
  • 17 Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purif 2017; 43 (1–3): 179-188
    CrossrefPubMedSearch in Google Scholar
  • 18 Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30 (06) 548-556
    CrossrefPubMedSearch in Google Scholar
  • 19 Calvert AH, Newell DR, Gumbrell LA. et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 (11) 1748-1756
    CrossrefPubMedSearch in Google Scholar
  • 20 Chatelut E, Rostaing L, Gualano V. et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron J 1994; 66 (02) 157-161
    CrossrefPubMedSearch in Google Scholar
  • 21 Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61 (04) 1495-1501
    CrossrefPubMedSearch in Google Scholar
  • 22 Levey AS, Stevens LA, Schmid CH. et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedSearch in Google Scholar
  • 23 Dooley MJ, Poole SG, Rischin D. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Ann Oncol 2013; 24 (11) 2746-2752
    CrossrefPubMedSearch in Google Scholar
  • 24 Port FK, Pisoni RL, Bragg-Gresham JL. et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22 (01) 175-180
    CrossrefPubMedSearch in Google Scholar
  • 25 De Leon A, Estevez R, Valero V. et al. Paclitaxel-associated hypersensitivity reactions: experience of the BrEAST trialists' group. Ann Oncol 2007; 18 (06) 1155-1161
    Search in Google Scholar
  • 26 Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. Kidney Int 2014; 86 (01) 34-39
    CrossrefPubMedSearch in Google Scholar
  • 27 Kliger AS, Foley RN, Goldfarb DS. et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013; 62 (05) 849-859
    CrossrefPubMedSearch in Google Scholar
  • 28 Chu E, DeVita Jr VT. Physicians' Cancer Chemotherapy Drug Manual 2024. 24th ed.. Burlington, MA: Jones & Bartlett Learning; 2024
    Search in Google Scholar
  • 29 Tai YH, Tai YJ, Hsu HC. et al. Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. Front Pharmacol 2017; 8: 800
    CrossrefPubMedSearch in Google Scholar
  • 30 Ramos-Casals M, Brahmer JR, Callahan MK. et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6 (01) 38
    CrossrefPubMedSearch in Google Scholar